Switch theme
Sign up to access all valuation multiples
St Pharm Co Ltd offers custom manufacturing services of Active pharmaceutical ingredients and their intermediates for their use in pharmaceutical development and be compliant to cGMP, requirements. The firm’s business areas include commercial manufacturing of new drug development, manufacturing of generic active pharmaceutical ingredients, fine chemical’s business and development of oligonucleotide therapeutics. The company’s products comprise small molecule active pharmaceutical ingredients, Anti-cancer, Anti- coagulant active pharmaceutical ingredients, etc.
2008
n/a
LTM Revenue $214M
LTM EBITDA $44.1M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ST Pharm has a last 12-month revenue (LTM) of $214M and a last 12-month EBITDA of $44.1M.
In the most recent fiscal year, ST Pharm achieved revenue of $199M and an EBITDA of $55.3M.
ST Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ST Pharm valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $214M | XXX | $199M | XXX | XXX | XXX |
| Gross Profit | $76.3M | XXX | $69.9M | XXX | XXX | XXX |
| Gross Margin | 36% | XXX | 35% | XXX | XXX | XXX |
| EBITDA | $44.1M | XXX | $55.3M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $25.2M | XXX | $20.1M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $25.0M | XXX | $25.2M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $37.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ST Pharm's stock price is KRW 79200 (or $58).
ST Pharm has current market cap of KRW 1.60T (or $1.2B), and EV of KRW 1.60T (or $1.2B).
See ST Pharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.2B | XXX | XXX | XXX | XXX | $1.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ST Pharm has market cap of $1.2B and EV of $1.2B.
ST Pharm's trades at 5.8x EV/Revenue multiple, and 21.0x EV/EBITDA.
Equity research analysts estimate ST Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ST Pharm has a P/E ratio of 46.4x.
See valuation multiples for ST Pharm and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 5.8x | XXX | XXX | XXX |
| EV/EBITDA | 26.3x | XXX | 21.0x | XXX | XXX | XXX |
| EV/EBIT | 46.1x | XXX | 57.6x | XXX | XXX | XXX |
| EV/Gross Profit | 15.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 46.4x | XXX | 46.0x | XXX | XXX | XXX |
| EV/FCF | 52.5x | XXX | 60.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialST Pharm's last 12 month revenue growth is 18%
ST Pharm's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
ST Pharm's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ST Pharm's rule of X is 67% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ST Pharm and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | 37% | XXX | 46% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 67% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ST Pharm acquired XXX companies to date.
Last acquisition by ST Pharm was XXXXXXXX, XXXXX XXXXX XXXXXX . ST Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ST Pharm founded? | ST Pharm was founded in 2008. |
| Where is ST Pharm headquartered? | ST Pharm is headquartered in South Korea. |
| Who is the CEO of ST Pharm? | ST Pharm's CEO is Mr. Moo-Je Sung. |
| Is ST Pharm publicy listed? | Yes, ST Pharm is a public company listed on KRX. |
| What is the stock symbol of ST Pharm? | ST Pharm trades under 237690 ticker. |
| When did ST Pharm go public? | ST Pharm went public in 2016. |
| Who are competitors of ST Pharm? | Similar companies to ST Pharm include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of ST Pharm? | ST Pharm's current market cap is $1.2B |
| What is the current revenue of ST Pharm? | ST Pharm's last 12 months revenue is $214M. |
| What is the current revenue growth of ST Pharm? | ST Pharm revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of ST Pharm? | Current revenue multiple of ST Pharm is 5.4x. |
| Is ST Pharm profitable? | Yes, ST Pharm is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ST Pharm? | ST Pharm's last 12 months EBITDA is $44.1M. |
| What is ST Pharm's EBITDA margin? | ST Pharm's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of ST Pharm? | Current EBITDA multiple of ST Pharm is 26.3x. |
| What is the current FCF of ST Pharm? | ST Pharm's last 12 months FCF is $22.1M. |
| What is ST Pharm's FCF margin? | ST Pharm's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of ST Pharm? | Current FCF multiple of ST Pharm is 52.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
